Skip to content

Study · Randomized controlled trial · 2011

4 results

Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Collins J, Murray E, Zaman K, Colleoni M and 5 more

Show all authors

Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A

Annals of oncology : official journal of the European Society for Medical Oncology16 Feb 2011Cited by 35 (Europe PMC)

PMID21325445 (opens in a new tab)PMCIDPMC3179412 (opens in a new tab)DOI10.1093/annonc/mdq735 (opens in a new tab)PepBankPUB-21325445
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In ER-positive breast cancer, CMF followed by goserelin improved disease-free survival versus CMF alone: 77% versus 69% at 12 years (P = 0.04).

    In plain wordsIn ER-positive breast cancer, adding goserelin after CMF improved disease-free survival versus CMF alone.

    Peptide
    Goserelin
    Outcome
    IncreaseDisease-free survival in ER-positive cohort
    Study

    n: not reported in source

    Comparator
    CMF alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Measurements

    12-year disease-free survival
    77%
    ER-positive, CMF then goserelin
    12-year disease-free survival
    69%
    ER-positive, CMF alone

    Source sentences

    Summary
    For the ER-positive cohort, sequential therapy provided a statistically significant benefit in disease-free survival (DFS) (12-year DFS = 77%) compared with CMF alone (69%) and goserelin alone (68%) (P = 0.04 for each comparison), due largely to the effect in younger patients.
    1 context sentence
    Summary · context
    From 1990 to 1999, 1063 patients were randomized to receive (i) goserelin for 24 months (n = 346), (ii) six courses of 'classical' CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy (n = 360), or (iii) six courses of CMF plus 18 months goserelin (CMF→ goserelin; n = 357).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In ER-positive breast cancer, goserelin alone had lower disease-free survival than sequential therapy: 68% versus 77% at 12 years (P = 0.04).

    In plain wordsIn ER-positive breast cancer, goserelin alone had lower disease-free survival than CMF followed by goserelin.

    Peptide
    Goserelin
    Outcome
    DecreaseDisease-free survival in ER-positive cohort
    Study

    n: not reported in source

    Comparator
    CMF followed by goserelin
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Measurements

    12-year disease-free survival
    68%
    ER-positive, goserelin alone
    12-year disease-free survival
    77%
    ER-positive, CMF then goserelin

    Source sentences

    Summary
    For the ER-positive cohort, sequential therapy provided a statistically significant benefit in disease-free survival (DFS) (12-year DFS = 77%) compared with CMF alone (69%) and goserelin alone (68%) (P = 0.04 for each comparison), due largely to the effect in younger patients.
    1 context sentence
    Summary · context
    From 1990 to 1999, 1063 patients were randomized to receive (i) goserelin for 24 months (n = 346), (ii) six courses of 'classical' CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy (n = 360), or (iii) six courses of CMF plus 18 months goserelin (CMF→ goserelin; n = 357).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In ER-negative breast cancer, goserelin alone had similar disease-free survival to CMF: 61% versus 67% at 12 years (P= NS).

    In plain wordsIn ER-negative breast cancer, disease-free survival was similar with goserelin alone and CMF alone.

    Peptide
    Goserelin
    Outcome
    No significant changeDisease-free survival in ER-negative cohort
    Study

    n: not reported in source

    Comparator
    CMF alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Measurements

    12-year disease-free survival
    61%
    ER-negative, goserelin alone
    12-year disease-free survival
    67%
    ER-negative, CMF alone

    Source sentences

    Summary
    Patients with ER-negative tumors whose treatment included CMF had similar DFS (12-year DFS CMF = 67%; 12-year DFS CMF→ goserelin = 69%) compared with goserelin alone (12-year DFS = 61%, P= NS).
    1 context sentence
    Summary · context
    From 1990 to 1999, 1063 patients were randomized to receive (i) goserelin for 24 months (n = 346), (ii) six courses of 'classical' CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy (n = 360), or (iii) six courses of CMF plus 18 months goserelin (CMF→ goserelin; n = 357).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In ER-negative breast cancer, goserelin alone had similar disease-free survival to sequential therapy: 61% versus 69% at 12 years (P= NS).

    In plain wordsIn ER-negative breast cancer, disease-free survival was similar with goserelin alone and CMF followed by goserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeDisease-free survival in ER-negative cohort
    Study

    n: not reported in source

    Comparator
    CMF followed by goserelin
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Measurements

    12-year disease-free survival
    61%
    ER-negative, goserelin alone
    12-year disease-free survival
    69%
    ER-negative, CMF then goserelin

    Source sentences

    Summary
    Patients with ER-negative tumors whose treatment included CMF had similar DFS (12-year DFS CMF = 67%; 12-year DFS CMF→ goserelin = 69%) compared with goserelin alone (12-year DFS = 61%, P= NS).
    1 context sentence
    Summary · context
    From 1990 to 1999, 1063 patients were randomized to receive (i) goserelin for 24 months (n = 346), (ii) six courses of 'classical' CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy (n = 360), or (iii) six courses of CMF plus 18 months goserelin (CMF→ goserelin; n = 357).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.